Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MCY-M11 |
Synonyms | |
Therapy Description |
MCY-M11 consists of autologous peripheral blood mononuclear cells modified to express an mRNA construct that encodes a mesothelin-targeting chimeric antigen receptor (CAR), which potentially induces phagocytosis and increases cytotoxicity against tumor cells expressing mesothelin (NCI Drug Dictionary; J Clin Oncol 2020 38:15_suppl, 3014). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCY-M11 | anti-mesothelin mRNA-transfected autologous PBMCs MCY-M11 | MCY-M11 consists of autologous peripheral blood mononuclear cells modified to express an mRNA construct that encodes a mesothelin-targeting chimeric antigen receptor (CAR), which potentially induces phagocytosis and increases cytotoxicity against tumor cells expressing mesothelin (NCI Drug Dictionary; J Clin Oncol 2020 38:15_suppl, 3014). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03608618 | Phase I | MCY-M11 Cyclophosphamide | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | Terminated | USA | 0 |